• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Repligen Corporation

    3/27/26 11:37:30 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGEN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 7)


    Repligen Corp

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    759916109

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    759916109


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Repligen Corp
    (b)Address of issuer's principal executive offices:

    41 Seyon Street, Building 1, Suite 100, Waltham, MA, 02453
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/27/2026
    Get the next $RGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RGEN

    DatePrice TargetRatingAnalyst
    6/2/2026$145.00Outperform
    Wolfe Research
    5/15/2026$160.00Outperform
    RBC Capital Mkts
    4/17/2026$160.00Buy
    Rothschild & Co Redburn
    10/1/2025$150.00Buy
    HSBC Securities
    9/22/2025$155.00In-line → Outperform
    Evercore ISI
    7/22/2025$160.00Overweight
    Stephens
    6/24/2025$150.00Overweight
    Barclays
    4/29/2025$160.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $RGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Repligen with a new price target

    Wolfe Research resumed coverage of Repligen with a rating of Outperform and set a new price target of $145.00

    6/2/26 8:37:34 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RBC Capital Mkts resumed coverage on Repligen with a new price target

    RBC Capital Mkts resumed coverage of Repligen with a rating of Outperform and set a new price target of $160.00

    5/15/26 8:30:16 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rothschild & Co Redburn initiated coverage on Repligen with a new price target

    Rothschild & Co Redburn initiated coverage of Repligen with a rating of Buy and set a new price target of $160.00

    4/17/26 8:13:33 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Madaus Martin D bought $201,830 worth of shares (1,800 units at $112.13) (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    8/12/25 12:47:07 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Pax Margaret bought $37,672 worth of shares (250 units at $150.69), increasing direct ownership by 32% to 1,043 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    3/18/25 3:58:05 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Madaus Martin D bought $201,776 worth of shares (1,615 units at $124.94) (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    6/14/24 6:07:59 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference

    WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3rd at 10:40 a.m. CT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a global life sciences company that de

    5/22/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report

    WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2025 Corporate Sustainability Report and related reporting framework disclosures. Themed "Driving Sustainable Growth Together", this report communicates the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Pathways to Success. Also included in the 2025 Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and three

    5/20/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference

    WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of America Securities 2026 Global Healthcare Conference, being held May 12-14 in Las Vegas, Nevada. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on May 12 at 10:00am PT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a globa

    5/7/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pax Margaret was granted 995 shares, increasing direct ownership by 49% to 3,011 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    5/18/26 4:05:06 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Eglinton Manner Carrie was granted 995 shares, increasing direct ownership by 22% to 5,461 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    5/18/26 4:05:07 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mhatre Rohin was granted 995 shares, increasing direct ownership by 25% to 5,014 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    5/18/26 4:05:07 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    SEC Filings

    View All

    Repligen Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - REPLIGEN CORP (0000730272) (Filer)

    5/15/26 8:09:23 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Repligen Corporation

    10-Q - REPLIGEN CORP (0000730272) (Filer)

    5/6/26 4:08:42 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REPLIGEN CORP (0000730272) (Filer)

    5/5/26 7:06:38 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Leadership Updates

    Live Leadership Updates

    View All

    908 Devices Appoints Christopher D. Brown to its Board of Directors

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

    6/16/25 8:00:00 AM ET
    $AAPL
    $MASS
    $RGEN
    Computer Manufacturing
    Technology
    Industrial Machinery/Components
    Industrials

    Repligen Appoints Jacob Johnson As Vice President Investor Relations

    WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the company's Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garland commented, "Jacob is a terrific addition to the Repligen team, bringing a broad understanding of the bioprocessing tools space, the markets we serve and the growth driver

    4/8/25 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

    BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

    12/16/24 8:11:00 AM ET
    $BLFS
    $RGEN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $RGEN
    Financials

    Live finance-specific insights

    View All

    Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

    First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-yearReiterating FY26 organic revenue growth guidance of 9%-13% and increasing adjusted EPS to $1.97-$2.05 WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2026, covering the three-month period ended March 31, 2026. The Company is also providing updated financial guidance for the full year 2026. Olivier Loeillot, President and Chief Executive Officer

    5/5/26 7:00:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen to Report First Quarter 2026 Financial Results

    WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended March 31, 2026. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. The w

    4/22/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

    Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVIDFull year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve-

    2/24/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Repligen Corporation

    SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

    11/14/24 1:22:37 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Repligen Corporation

    SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

    9/10/24 5:08:30 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

    SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

    2/14/24 10:02:59 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care